| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-10 |
| filingDate |
2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-WO2018143315-A1 |
| titleOfInvention |
Quinazoline compounds |
| abstract |
Disclosed is a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [MEANS FOR SOLVING PROBLEMS] The present inventors have investigated compounds useful as an active ingredient in a pharmaceutical composition for treating lung cancer, and that quinazoline compounds have excellent G12C mutant KRAS inhibitory activity and can be used as therapeutic agents for lung cancer. As a result, the present invention was completed. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for lung cancer. [Selection figure] None |
| priorityDate |
2017-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |